Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29486393 | 1.00 | DAO (0.56) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL29486398 | 1.00 | DAO (0.56) | DAOAXLNUDT1AURKAPARP1 | |
| Trifluoroacetic Acid SCHEMBL29713497 | 0.86 | DAO (0.48) | DAORIPK1 | |
| SCHEMBL5794083 | 0.76 | DAO (0.47) | DAOAXLNUDT1RIPK1CCNB2 | |
| SCHEMBL4429036 | 0.74 | MAPT (0.50) | — | |
| SCHEMBL29498319 | 0.73 | DAO (0.53) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL126973 | 0.73 | DAO (0.53) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL491810 | 0.73 | PARP1 (0.42) | NUDT1AURKAPARP1 | |
| SCHEMBL5413200 | 0.73 | PARP1 (0.42) | NUDT1AURKAPARP1 | |
| Hydrochloric Acid SCHEMBL7181738 | 0.72 | DAO (0.51) | DAOAXLNUDT1AURKAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883579-B1 | COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | AMGEN INC (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2022111644-A1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-02 | — | — | WO | claimed |
| JP-4034811-B2 | — | — | 2008-01-16 | — | — | JP | claimed |
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | Ricerca Biosciences, LLC | 2007-04-12 | — | — | US | claimed |
| JP-2007503386-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | claimed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | claimed |
| US-20030235631-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2003-12-25 | — | — | US | claimed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | claimed |
| EP-4709853-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-18 | — | — | EP | disclosed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2025242031-A1 | USE OF COMBINATION OF PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE DERIVATIVE IN PREVENTING OR TREATING TUMOR DISEASE | 上海翰森生物医药科技有限公司 | 2025-11-27 | — | — | WO | disclosed |
| EP-0885894-A1 | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-4859672-A | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone | RORER PHARMACEUTICAL CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
| US-4224328-A | Methods with 1-substituted-4-aryl-quinazolin-2(1H)-ones and thiones and pyrido[2,3-d]pyrimidin-2-ones as platelet aggregation inhibitors | SANDOZ, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4224328-A | Methods with 1-substituted-4-aryl-quinazolin-2(1H)-ones and thiones and pyrido[2,3-d]pyrimidin-2-ones as platelet aggregation inhibitors | SANDOZ, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4009166-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, CNS DEPRESSANTS | HISAMITSU PHARMACEUTICAL CO., INC. (JA) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | DAO 2963/4885AXL 497/4885NUDT1 1560/4885 |
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | DAO 847/4885AXL 2134/4885NUDT1 2913/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DAO 3983/4885AXL 3344/4885NUDT1 1635/4885 |
| US-20030235631-A1 | Combination treatment for depression and anxiety | PDE3B, PDE2A, PDE3A | DAO 161/4885AXL 4165/4885NUDT1 1447/4885 |
| US-20070082920-A1 | NAD+-dependent DNA ligase inhibitors | LIG3, LIG1, NQO1 | DAO 335/4885AXL 3769/4885NUDT1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.